Evidence guide · US

NAD+ drips: contamination warnings, regulators and what the evidence shows

Singapore's HSA has warned against NAD+ drips sold on social media. FDA says severe chills and shaking after NAD+ injections are consistent with excessive endotoxins, and that food-grade NAD+ is not suitable for sterile drugs without appropriate processing. What regulators have flagged and what the human evidence shows.

Review type: research summary. This page summarises published research and product labels, cited below.

Singapore's Health Sciences Authority (HSA) has advised consumers not to use intravenous drip treatments promoted online or on social media, after advertisements for intravenous supplements claiming to "reverse aging" and "relieve fatigue" appeared there, some offering injections at home. Those advertisements included NAD+ and vitamins. In a statement reported by Lianhe Zaobao on November 14 and 15, 2026, HSA said it "has not approved any intravenous (IV) health product containing NAD+ or NMN for use in Singapore" and that "to date, there is no clinical evidence on the effectiveness of IV NAD+ or NMN for the treatment of various medical conditions."

Short answer: the warning is about a real and documented problem. In the United States, FDA has received adverse event reports after NAD+ injections, including severe chills, shaking, vomiting and fatigue, with some requiring medical treatment, and says these reactions are consistent with excessive endotoxins. It also says food-grade NAD+ is not suitable for compounding sterile drugs without appropriate processing. No randomized trial has shown that NAD+ drips improve energy, wellbeing or aging.

What NAD+ is, and why it is sold as a drip

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell uses in energy metabolism. It is sold as oral capsules of its building blocks, such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), and, in wellness clinics and drip bars, as NAD+ itself in injections and intravenous drips. A drip is not a food supplement: it is a sterile product put straight into a vein, which is why the contamination questions below matter.

What FDA has flagged

  • Food-grade ingredients: in a notice with content current as of October 30, 2024, FDA said it is aware of compounders using food-grade NAD+ sold by repackagers to make intravenous products, and that ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing "due to the high risk of contamination with microbes and endotoxins".
  • Reactions: the same notice says FDA has received adverse event reports following use of NAD+ injectable drugs, "including severe chills, shaking, vomiting and fatigue with some requiring medical treatment", and that these reactions are consistent with excessive levels of endotoxins. The notice does not give a number of reports.
  • One facility: a warning letter dated January 20, 2026 to GenoGenix LLC, an outsourcing facility in Florida, records a complaint that three patients developed low blood pressure, uncontrollable shaking, shivers and body aches during or shortly after receiving a compounded NAD+ product from the same vial, and were directed to the emergency room. An unopened vial from the same lot contained excessive bacterial endotoxins, with a reported value of 3,360 EU/mL. The letter says the firm did not perform any finished-product testing on that NAD+ product before release, that NAD+ does not appear on the 503B bulks list and was not used to compound a drug on the drug shortage list, and that on July 30, 2025 the firm initiated a voluntary recall of drug products intended or expected to be sterile, within expiry, and has ceased drug production.
  • Recalls: the openFDA enforcement reports for products described as nicotinamide adenine dinucleotide list 14 recalls. The earliest report date is January 11, 2017, for a Wells Pharmacy NADH injection whose recall was initiated on September 21, 2016. The earliest NAD+ report is dated January 17, 2018, for a KRS Global recall initiated on November 16, 2017. Nine of the 14 cite lack of assurance of sterility. The other five cite labeling or a beyond-use date, potency or reconstitution time, a CGMP deviation, or elevated endotoxin. They include a Class I recall of GenoGenix NAD+ for injection for elevated endotoxin levels (D-0094-2026), reported on October 15, 2025, and two recalls of NAD+ pre-filled syringes from Thrive Health Solutions in Colorado (D-0478-2025 and D-0487-2025), both reported on July 2, 2025 for lack of assurance of sterility.

These records describe specific products and facilities. They are not a finding that every NAD+ drip is contaminated, but they show why the source and sterility of what goes into the bag matter more for a drip than for a capsule.

What the human evidence shows

  • No outcome trials: a 2026 systematic review of 33 human intervention studies found that oral NR and NMN consistently raised NAD-related markers, but identified no eligible outcome trials of intravenous or intramuscular NAD+ for anti-aging or wellness. One author reports being an owner of a management services organization that provides administrative services to an aesthetics clinic, Allure Aesthetics, which the review says does not offer NAD+ infusions or NAD+ supplementation.
  • Where infused NAD+ goes: in a 2019 pilot study of a six-hour NAD+ infusion at 3 micromoles per minute, plasma NAD+ and its metabolites did not change until after two hours. The paper says that, at that infusion rate, NAD+ is "rapidly and completely removed from the plasma" for at least the first two hours.
  • Tolerability: a 2026 retrospective review of records from Restore Hyperwellness in Austin compared four consecutive days of 500 mg IV NAD+ with 500 mg IV NR. All six people given NAD+ reported moderate to severe abdominal cramping, diarrhea, nausea and vomiting, a raised heart rate and chest pressure during the infusions, and the NAD+ drips took longer to give, averaging 97 minutes against 37 minutes for NR in the group of eight. All symptoms resolved when the infusions ended. The authors call the cohort small, there was no placebo group, and every author was employed by Restore Hyperwellness.
  • Oral comparison: in a randomized open-label trial in healthy adults, whose authors say a direct comparison of NAD+ precursors in humans had been lacking, 1,000 mg a day of oral NR or NMN for 14 days roughly doubled whole-blood NAD+. Raising a blood marker is not the same as an improvement people notice, and the 2026 review found those effects often absent.

Questions to ask before any NAD+ drip or injection

  • Who is prescribing it, and have they reviewed my medical history and medicines?
  • What exactly is in the bag or syringe, who made it, and is the NAD+ food grade, or suitable for a sterile drug?
  • Is the product a licensed medicine where I live, or prepared for me individually by a licensed pharmacy?
  • What human evidence supports the benefit being promised, and was it a randomized trial?
  • How fast will it run, who is supervising, and what happens if I get chills, shaking, chest tightness or a racing heart?

Our view

  • The marketing has run ahead of the evidence. There is no randomized trial showing that NAD+ drips make people feel or function better.
  • The documented risks are specific: contaminated or non-sterile products and unpleasant symptoms during the infusion. Home injections offered on social media, including injections at home without a health assessment, sit outside the checks above.
  • If the aim is to raise blood NAD+, oral NR and NMN do that in trials, without a needle.
  • Severe chills or shaking, chest pressure or a racing heart during or after a drip need prompt medical attention.
  • Speak to a doctor or pharmacist before using any NAD+ product, especially if you take regular medicines.

US rules

FDA's compounding notice calls NAD+ injections drugs, and says ingredients identified for foods or dietary supplements are not suitable for sterile drugs without appropriate processing. The GenoGenix warning letter says that firm had no FDA-approved application for the drug products it compounded, and that NAD+ does not appear on the 503B bulks list and was not used to compound a drug on the drug shortage list. FDA encourages health care professionals, compounders and patients to report adverse events with NAD+ injectable drugs to its MedWatch Adverse Event Reporting program.

FAQ

Do NAD+ drips work?

They have not been shown to. A 2026 systematic review found no eligible outcome trials of intravenous NAD+ for anti-aging or wellness, and Singapore's HSA said there is no clinical evidence on the effectiveness of IV NAD+ or NMN for treating medical conditions.

Why do some people shake or get chills during an NAD+ drip?

FDA says the severe chills, shaking, vomiting and fatigue in the reports it received after NAD+ injections are consistent with excessive endotoxins. The notice does not give a number of reports. Separately, in the Austin clinic records study, all six people given NAD+ reported nausea, abdominal cramping, a raised heart rate and chest pressure while the infusion ran. Tell the person supervising the drip straight away if you feel unwell.

Is an NAD+ drip better than an NMN or NR supplement?

There is no evidence that it is. Oral NR and NMN raise blood NAD+ in trials, while IV NAD+ has no outcome trials and carries the risks of an infusion.

Sources

These are the documents this page relies on.

  1. HSA warns against 'anti-aging' IV supplements advertised on social media (November 15, 2026)Lianhe Zaobao
  2. 社媒出现“抗衰老”输液补剂广告 卫科局警告勿贸然注射 (Chinese-language report, November 14, 2026)Lianhe Zaobao
  3. FDA reminds compounders to use ingredients suitable for sterile compounding (content current as of October 30, 2024)US Food and Drug Administration
  4. Warning letter to GenoGenix LLC, 718739, January 20, 2026US Food and Drug Administration
  5. Drug recall enforcement reports for nicotinamide adenine dinucleotide products (openFDA)US Food and Drug Administration
  6. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci. 2019;11:257Frontiers in Aging Neuroscience (PubMed 31572171)
  7. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582Frontiers in Aging (PubMed 41704678)
  8. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026;116:103057Ageing Research Reviews (PubMed 41655607)
  9. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026;8:62-73Nature Metabolism (PubMed 41540253)
  10. MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramUS Food and Drug Administration